Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $116,350.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $116.35, for a total value of $116,350.00. Following the completion of the sale, the chief executive officer now owns 439,307 shares of the company’s stock, valued at approximately $51,113,369.45. The trade was a 0.23 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $111.17 on Wednesday. The firm has a market cap of $6.85 billion, a PE ratio of 15.66, a PEG ratio of 1.04 and a beta of 0.38. The stock has a 50 day moving average of $121.47 and a 200 day moving average of $122.47. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. During the same quarter in the prior year, the company posted $2.68 earnings per share. The firm’s revenue was down .5% compared to the same quarter last year. On average, research analysts expect that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Versant Capital Management Inc lifted its holdings in shares of Jazz Pharmaceuticals by 9.4% in the 1st quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company’s stock valued at $131,000 after acquiring an additional 91 shares during the last quarter. Bessemer Group Inc. lifted its stake in shares of Jazz Pharmaceuticals by 0.3% in the 4th quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company’s stock valued at $3,317,000 after purchasing an additional 92 shares during the last quarter. Kendall Capital Management lifted its stake in shares of Jazz Pharmaceuticals by 1.2% in the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company’s stock valued at $989,000 after purchasing an additional 95 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in shares of Jazz Pharmaceuticals by 5.2% in the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock worth $243,000 after purchasing an additional 97 shares during the period. Finally, Synovus Financial Corp increased its position in shares of Jazz Pharmaceuticals by 0.5% during the 4th quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company’s stock valued at $2,365,000 after purchasing an additional 100 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Morgan Stanley reissued an “overweight” rating and issued a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Needham & Company LLC reiterated a “buy” rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, April 10th. Finally, Truist Financial boosted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.